Escalating dengue in Bangladesh: An analytical assessment of environmental and socioeconomic drivers
American Journal of Biopharmacy and Pharmaceutical Sciences · 09.03.2026 · 6 · 4
DOI: 10.25259/ajbps_22_2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Biopharmacy and Pharmaceutical Sciences, online erschienen am 09.03.2026. Verfasst von Abdul Kader Mohiuddin. Die Arbeit nennt 111 Literaturangaben.
Abstract (Originalsprache)
Dengue has emerged as a persistent and escalating public health crisis in Bangladesh, reflecting both local vulnerabilities and a broader global threat. Between 2018 and 2025, the outbreaks have caused substantial morbidity and mortality across all age groups, driven by rapid urbanization, dense populations, poor sanitation, and climatic changes. Environmental degradation, including loss of green cover, pollution, and plastic accumulation, has further intensified mosquito proliferation, while demographic shifts reveal increasing vulnerability among children, juveniles, and young adults. Immediate, coordinated action – including strengthened public health infrastructure, vector control, and community awareness – is imperative to curb the ongoing outbreaks and mitigate the potential for regional and global spread.
Zitieren
APA
Mohiuddin, A. K. (2026). Escalating dengue in Bangladesh: An analytical assessment of environmental and socioeconomic drivers. American Journal of Biopharmacy and Pharmaceutical Sciences, 6, 4. https://doi.org/10.25259/ajbps_22_2025
Vancouver
Mohiuddin AK. Escalating dengue in Bangladesh: An analytical assessment of environmental and socioeconomic drivers. American Journal of Biopharmacy and Pharmaceutical Sciences. 2026;6:4. doi:10.25259/ajbps_22_2025
BibTeX
@article{Mohiuddin2026,
author = {Mohiuddin, Abdul Kader},
title = {Escalating dengue in Bangladesh: An analytical assessment of environmental and socioeconomic drivers},
journal = {American Journal of Biopharmacy and Pharmaceutical Sciences},
year = {2026},
volume = {6},
pages = {4},
doi = {10.25259/ajbps_22_2025}
}
EUVIMED